Atypical antipsychotics and anorexia nervosa: A review
| Autor: | Rebecca F. McKnight, Rebecca J. Park |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Olanzapine
medicine.medical_specialty Anorexia Nervosa Risperidone medicine.drug_class Atypical antipsychotic Weight Gain medicine.disease Psychiatry and Mental health Clinical Psychology Eating disorders Anorexia nervosa (differential diagnoses) Practice Guidelines as Topic medicine Humans Anxiety Quetiapine medicine.symptom Psychiatry Psychology Antipsychotic Agents Randomized Controlled Trials as Topic medicine.drug Clinical psychology Psychopathology |
| Zdroj: | European Eating Disorders Review. 18:10-21 |
| ISSN: | 1099-0968 1072-4133 |
| DOI: | 10.1002/erv.988 |
| Popis: | Background There is currently mixed opinion regarding the value of using atypical antipsychotics to treat anorexia nervosa (AN). Aims To evaluate the literature on the use of atypical antipsychotics in AN. Method A review of all studies and clinical guidelines published before September 2009 involving use of an atypical antipsychotic in patients with AN. Analysis is by narrative synthesis. Results Forty-three publications or study protocols were found, including four randomized-controlled trials, five open-label trials and 26 case reports. The most studied drugs were olanzapine, quetiapine and risperidone. Atypical antipsychotics appear safe and there is some evidence of positive effects on depression, anxiety and core eating disordered psychopathology in patients with anorexia nervosa. Currently there is insufficient evidence to confirm atypical antipsychotics enhance weight gain in this setting. Conclusions Further high quality evidence is needed in this area in order to provide practical guidance to clinicians. However, the main challenge is to persuade adequate numbers of AN patients to participate in research trials. Copyright © 2010 John Wiley & Sons, Ltd and Eating Disorders Association. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text